Tactile Medical acquires LymphaTech for $6.8 million

Reuters
16 hours ago
Tactile Medical acquires LymphaTech for $6.8 million

Tactile Systems Technology Inc. has acquired LymphaTech Inc. for an upfront payment of $6.8 million, with potential additional payments based on future milestones. The deal brings LymphaTech’s 3D body measurement and monitoring platform for lymphedema into Tactile Medical’s portfolio, expanding its digital and research capabilities. LymphaTech’s co-founders, Mike Weiler, PhD, and Nate Frank, MBA, have joined Tactile Medical to support commercial adoption and ongoing research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tactile Systems Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656036-en) on February 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10